How should I cross‑titrate a patient on brexpiprazole (Rexulti) for anger to a less expensive antipsychotic?

Switching from Brexpiprazole (Rexulti) to a Less Expensive Antipsychotic

When switching a patient from brexpiprazole to a more affordable antipsychotic due to cost concerns, perform a gradual cross-titration over 22-33 days, as this timeframe is associated with the lowest incidence of adverse events and successful conversion. 1

Cross-Titration Strategy

Recommended Timeline and Method

• Initiate the new antipsychotic while gradually tapering brexpiprazole over 3-4 weeks (22-33 days), as this approach demonstrated the lowest rate of treatment-emergent adverse events (44.4%) compared to faster switches (62.5-84.2% with shorter conversion periods). 1

• The cross-titration should be informed by the half-life and receptor profile of each medication, ensuring pharmacodynamic compatibility during the transition. 2

• Brexpiprazole has a long half-life (approximately 91 hours), which supports a gradual taper and reduces the risk of withdrawal symptoms or symptom exacerbation. 3

Selecting the Alternative Antipsychotic

Since brexpiprazole is a D2 partial agonist, switch to an antipsychotic with a different pharmacodynamic profile—specifically amisulpride, risperidone, paliperidone, or olanzapine (with concurrent metformin to mitigate weight gain). 2

• Risperidone or paliperidone are cost-effective options that have demonstrated successful switching outcomes from brexpiprazole with medication persistence rates of 72.5% at 12 weeks. 4

• Olanzapine (with metformin) is another viable alternative with an even higher persistence rate of 84.6% when switching from brexpiprazole, though metabolic monitoring is essential. 4

• Avoid switching to another D2 partial agonist (such as aripiprazole or cariprazine) as guidelines recommend changing pharmacodynamic profiles when switching antipsychotics. 2

Practical Cross-Titration Protocol

Week 1-2: Initiation Phase

• Start the new antipsychotic at a low therapeutic dose while maintaining full-dose brexpiprazole. 1
• For risperidone: begin at 1-2 mg/day; for paliperidone: begin at 3 mg/day; for olanzapine: begin at 5-10 mg/day with metformin 500 mg twice daily. 2

Week 2-3: Cross-Titration Phase

• Gradually increase the new antipsychotic to target therapeutic dose. 1
• Begin tapering brexpiprazole by 50% (e.g., from 2 mg to 1 mg daily). 1

Week 3-4: Completion Phase

• Continue increasing the new antipsychotic to full therapeutic dose. 1
• Complete brexpiprazole taper to discontinuation by day 22-33. 1

Monitoring During Transition

Symptom Monitoring

• Assess for symptom exacerbation weekly during the cross-titration period, as inadequate response should be identified within 4 weeks at therapeutic doses. 2

• Monitor specifically for anger/irritability symptoms, as brexpiprazole has demonstrated efficacy for irritability in mood disorders, and symptom worsening may occur after discontinuation. 5

Safety Monitoring

• Monitor for extrapyramidal symptoms (EPS), akathisia, and sedation, particularly when switching to risperidone or paliperidone, which have higher EPS risk than brexpiprazole. 3, 6

• Assess orthostatic blood pressure and fall risk, especially in the first 2 weeks, as both brexpiprazole withdrawal and new antipsychotic initiation can affect blood pressure regulation. 3

• Implement metabolic monitoring (weight, glucose, lipids) at baseline and 12 weeks when switching to olanzapine, risperidone, or paliperidone. 2

Common Pitfalls to Avoid

Avoid Abrupt Discontinuation

• Never abruptly stop brexpiprazole, as this increases the risk of symptom relapse and withdrawal effects, particularly given its long half-life. 1

Avoid Same-Class Switches

• Do not switch to aripiprazole or cariprazine (other D2 partial agonists) as guidelines specifically recommend switching to compounds with different pharmacodynamic profiles. 2

Avoid Inadequate Titration Time

• Switches completed in less than 2 weeks (8-14 days) showed higher adverse event rates (84.2%) compared to the recommended 22-33 day period. 1

Shared Decision-Making

• Engage the patient in collaborative decision-making regarding the alternative antipsychotic choice, weighing cost considerations against side-effect profiles, dosing convenience, and availability of long-acting formulations. 2

• Cost and availability of treatments are legitimate factors in antipsychotic selection, and guidelines explicitly acknowledge that financial constraints may determine which treatment options can be considered. 2

• Discuss the rationale for the gradual cross-titration approach to set realistic expectations about the 3-4 week transition period and the importance of adherence during this time. 1